Story perspectives

KCL-286 Repairs DNA, Reduces Inflammation in Alzheimer Mice

7/18/2026

Summary

Story summary

King's College London researchers reported that KCL-286 repaired DNA breaks, reduced brain inflammation, and activated the retinoic acid receptor-beta pathway in early-stage Alzheimer’s mouse models.
The compound raised BRCA1 protein levels and cleared Phase I safety trials, enabling faster clinical development for Alzheimer’s.
Professor Jonathan Corcoran said a proof-of-concept trial with about 20 patients could begin within a year if funding is secured.

1 of 1

Story summary

King's College London researchers reported that KCL-286 repaired DNA breaks, reduced brain inflammation, and activated the retinoic acid receptor-beta pathway in early-stage Alzheimer’s mouse models.
The compound raised BRCA1 protein levels and cleared Phase I safety trials, enabling faster clinical development for Alzheimer’s.
Professor Jonathan Corcoran said a proof-of-concept trial with about 20 patients could begin within a year if funding is secured.